AURA Form 144: Proposed sale of 15,890 shares

Aura Biosciences reported a Form 144 notice for a proposed sale of common stock.

Rhea-AI Filing Summary

Aura Biosciences reported a Form 144 notice for a proposed sale of common stock. The filing lists 15,890 shares with Morgan Stanley Smith Barney LLC as the broker and a filing date of 02/17/2026. The excerpt also shows restricted stock unit awards of 7,129 (granted 02/01/2024) and 22,619 (granted 02/03/2025).

Insights

Insider-Transactions Specialist

Form 144 lists a proposed insider sale of common stock using Morgan Stanley as broker.

The filing records 15,890 shares and identifies Morgan Stanley Smith Barney LLC as the broker with a filing date of 02/17/2026. This form notifies the SEC of an intended sale under Rule 144; it does not confirm execution.

Restricted stock unit grants shown — 7,129 (02/01/2024) and 22,619 (02/03/2025) — are listed as awards subject to vesting. Timing and cash‑flow outcomes depend on whether and when the reported sales are executed in the market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Aura Biosciences' Form 144 disclose?

The Form 144 discloses a proposed sale of 15,890 shares of common stock via Morgan Stanley Smith Barney LLC, with a filing date of 02/17/2026. It also lists RSU awards of 7,129 and 22,619 granted on 02/01/2024 and 02/03/2025.

Does the Form 144 confirm the shares were sold?

No. The Form 144 functions as a notice of an intended sale under Rule 144 and does not confirm execution. The filing lists the proposed sale details, but actual trade execution and settlement are not reported in this excerpt.

Who is the broker named on the Aura Form 144?

The broker named is Morgan Stanley Smith Barney LLC, shown alongside the listed 15,890 shares and the filing date 02/17/2026. The broker is identified as the intermediary for the proposed transaction in the notice.

What are the restricted stock units listed in the filing?

The filing shows restricted stock unit awards: 7,129 units granted on 02/01/2024 and 22,619 units granted on 02/03/2025. Each award is described as subject to vesting requirements under the company plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001868719
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Aura Biosciences, Inc.
SEC File Number	001-40971
Address of Issuer	80 Guest Street Boston MASSACHUSETTS 02135
Phone	617-500-8864
Name of Person for Whose Account the Securities are To Be Sold	Plavsic Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Drive 200 West Civic Center 4th Floor Sandy UT 84070	15890	80270.85	63503269	02/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/01/2024	Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.	Aura Biosciences, Inc.			7129	02/01/2024	N/A
Common Stock	02/03/2025	Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.	Aura Biosciences, Inc.			22619	02/03/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales reported on this Form 144 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Date of Notice	02/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Amy Elazzouzi, as Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)